EHA 2022 | Lower-intensity frontline therapy for newly diagnosed AML
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II study of lower-intensity frontline therapy for patients with newly diagnosed acute myeloma leukemia (AML) who are unfit or ineligible for clinical trials. Patients with newly diagnosed disease often present with abnormal organ function, amongst other factors which excludes patients from clinical trials. This study treated patients with a lower-intensity regimen of cladribine plus low-dose cytarabine (LDAC) alternated with decitabine (DAC), and included patients assessed against less stringent inclusion criteria. The study showed that treatment with cladribine plus LDAC was feasible and produced high response rates in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier
Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron
Speaker’s Bureau: Cure, Hikma
Honoraria: Genzyme
